Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low at $1.16

Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$1.16 and last traded at C$1.18, with a volume of 101382 shares. The stock had previously closed at C$1.19.

Wall Street Analyst Weigh In

Separately, Raymond James raised their target price on Oncolytics Biotech from C$3.00 to C$3.50 in a research note on Friday, September 20th.

Oncolytics Biotech Price Performance

The stock has a fifty day simple moving average of C$1.32 and a 200-day simple moving average of C$1.41. The company has a market capitalization of C$90.69 million, a PE ratio of -3.13 and a beta of 1.38. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings data on Thursday, August 1st. The company reported C($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of C($0.10). Equities analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.